Table 1 Patients´ characteristics and cancer type by site
From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America
Argentina | Brazil | Chile | Honduras | Mexico | Combined | |
|---|---|---|---|---|---|---|
N = 156 | N = 286 | N = 154 | N = 36 | N = 151 | N = 783 | |
Sex (n = 783), % (n) | ||||||
Female | 12% (19) | 23% (67) | 9% (14) | 53% (19) | 14% (21) | 18% (140) |
Male | 88% (137) | 77% (219) | 91% (140) | 47% (17) | 86% (130) | 82% (643) |
Age at cancer diagnosis (n = 783), median (IQR) | 38 (33–45) | 41 (35–48) | 39 (33–49) | 41 (30–48) | 34 (29–42) | 39 (32–47) |
Years from HIV diagnosis to cancer diagnosis (n = 772), median (IQR) | 1.79 (0.10–5.94) | 3.97 (0.25–9.95) | 1.88 (0.38–7.05) | 1.60 (0.41–4.69) | 0.45 (0.06–2.77) | 1.67 (0.18–6.74) |
Years from cART initiation to cancer diagnosis (n = 749), median (IQR) | 0.040 (− 0.080–2.49) | 0.53 (− 0.02–5.86) | 0.33 (− 0.04–1.93) | 0.53 (− 0.04–2.30) | −0.010 (− 0.09–0.93) | 0.19 (− 0.06–2.87) |
Cancer diagnosis relative to cART initiation (n = 783), % (n) | ||||||
Cancer diagnosis after cART initiation | 53% (83) | 64% (183) | 63% (97) | 64% (23) | 46% (69) | 58% (455) |
Cancer diagnosis before/at cART initiation/Did not start cART | 47% (73) | 36% (103) | 37% (57) | 36% (13) | 54% (82) | 42% (328) |
CD4 count (cells/μL) at cancer diagnosis (n = 537), median (IQR) | 82 (14–276) | 190 (54–425) | 171 (56–388) | 176 (90–382) | 141 (45–300) | 148 (44–364) |
HIV-1 RNA at cancer diagnosis (log10) (n = 422), median (IQR) | 4.4 (2.6–5.3) | 3.2 (2.6–4.9) | 2.6 (2.6–4.9) | 2.6 (2.6–4.4) | 4.6 (2.6–5.3) | 3.9 (2.6 5.0) |
HIV1-RNA status at cancer diagnosis (cut point = 400 copies/mL), % (n) | ||||||
Undetectable | 31% (16) | 49% (80) | 49% (41) | 67% (6) | 38% (43) | 44% (186) |
Detectable | 69% (36) | 51% (84) | 51% (43) | 33% (3) | 62% (70) | 56% (236) |
Status at the end of follow-up (n = 783), % (n) | ||||||
Alive | 81% (126) | 61% (174) | 67% (103) | 61% (22) | 84% (127) | 70% (552) |
Dead | 19% (30) | 39% (112) | 33% (51) | 39% (14) | 16% (24) | 30% (231) |
Follow-up (years) (n = 783), median (IQR) | 2.20 (0.55–6.13) | 2.30 (0.66–4.91) | 3.69 (0.62–8.87) | 1.06 (0.59–5.42) | 3.33 (0.92–5.84) | 2.51 (0.69–6.13) |
Type of cancer (n = 783), % (n) | ||||||
AIDS-defining cancers | 82% (128) | 66% (188) | 70% (108) | 72% (26) | 75% (114) | 72% (564) |
Kaposi sarcoma | 59% (92) | 51% (147) | 42% (65) | 28% (10) | 42% (64) | 48% (378) |
Non-Hodgkin lymphoma | 20% (31) | 13% (38) | 27% (41) | 19% (7) | 22% (33) | 19% (150) |
Invasive cervical cancer | 3% (5) | 1% (3) | 1% (2) | 25% (9) | 11% (17) | 5% (36) |
Non-AIDS-defining cancers | 18% (28) | 34% (98) | 30% (46) | 28% (10) | 25% (37) | 28% (219) |
Anal | 2% (3) | 5% (15) | 3% (4) | 3% (1) | 13% (19) | 5% (42) |
Breast | 1% (2) | 5% (15) | 1% (1) | 6% (2) | 0% (0) | 3% (20) |
Colon | 1% (2) | 1% (3) | 2% (3) | 3% (1) | 0% (0) | 1% (9) |
Hodgkin lymphoma | 2% (3) | 1% (4) | 6% (9) | 0% (0) | 5% (7) | 3% (23) |
Lung | 3% (4) | 3% (8) | 0% (0) | 0% (0) | 0% (0) | 2% (12) |
Prostate | 0% (0) | 2% (5) | 1% (1) | 3% (1) | 3% (5) | 2% (12) |
Renal | 1% (2) | 2% (6) | 0% (0) | 0% (0) | 0% (0) | 1% (8) |
Skin | 4% (7) | 7% (20) | 5% (7) | 6% (2) | 1% (1) | 5% (37) |
Testicular | 1% (1) | 0% (0) | 5% (7) | 0% (0) | 0% (0) | 1% (8) |
Othera | 3% (4) | 8% (22) | 9% (14) | 8% (3) | 3% (5) | 6% (48) |